Authors

Latest:

Cleveland Clinic and IBM Researchers Publish Findings on Artificial Intelligence and Immunity

The study, published in Briefings in Bioinformatics, highlights how artificial intelligence can be designed to develop better immunotherapy treatments.

Eugenia Girda, MD

Latest:

Dr Girda on the Use of Pembrolizumab Plus Chemotherapy in Endometrial Cancer

Eugenia Girda, MD, FACOG, discusses the use of pembrolizumab plus chemotherapy for patients with endometrial cancer as seen in the phase 3 NRG-GY018 trial.

Robert J. Lewandowski, MD, FSIR

Latest:

Novel Strategies: Combining Systemic and Local Therapies

Ghassan Abou-Alfa, MD, Robert Lewandowski, MD, FSIR, and Amit Singal, MD discuss potential novel combination therapies including immune checkpoint inhibitors plus tyrosine kinase inhibitors plus local-regional therapeutic strategies.

Jenny Paredes, PhD

Jenny Paredes, PhD is a microbiologist and staff Scientist at City of Hope.

Latest:

Dr Paredes on the Association Between Fiber Intake and Improved Survival With Reduced GI aGVHD After Allo-HCT

Jenny Paredes, PhD, discusses how increased dietary fiber was associated with improved 24-month survival and reduced lower GI aGVHD in allo-HCT recipients.

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN

Latest:

Dr. Neumann on Tapering Steroids in cGVHD

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses tapering steroids for patients with chronic graft-vs-host disease.

Amy W. Zhou, MD

Latest:

Dr Zhou on Ongoing Investigations into the Treatment of Patients With Myelofibrosis and Anemia

Amy W. Zhou, MD, discusses ongoing and planned trials that may enhance therapeutic options for patients with myelofibrosis and anemia that are currently taking place at the Washington University School of Medicine in St. Louis.

Gary Ulaner, MD, PhD

Latest:

FES-PET in the Treatment of Patients with Breast Cancer: Clinical Case 2

Dr Jeremy Force illustrates how FES-PET aids in the treatment of patients with breast cancer through a clinical case.

S. Alex Mastroyannis, MD, MSCE

Latest:

Dr Mastroyannis on the Continued Investigation of Targeted Therapies in Ovarian Cancer

S. Alex Mastroyannis, MD, MSCE, discusses the management of gynecologic cancers, such as metastatic or recurrent ovarian and endometrial cancers.

Wendy Stock, MD

Latest:

Women in Oncology: Prioritization and Passionate Legacies

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

Thierry Facon, MD

Thierry Facon, MD, is a professor of hematology in the Department of Hematology at Lille University Hospital in France.

Latest:

Dr Facon on the Rationale for Evaluating Isa-VRd in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

Thierry Facon, MD, details the rationale for evaluating Isa-VRd in patients with transplant-ineligible, newly diagnosed multiple myeloma.

Yang Yang Hartwich, PhD

Latest:

Dr Hartwich on Preclinical Findings for Y3 Plus Chemotherapy in Ovarian Cancer

Yang Yang Hartwich, PhD discusses a study delving into the mechanisms underlying chemoresistance in ovarian cancer.

Laura Finn, MD

Latest:

Dr. Finn on the Utility of Belantamab Mafodotin in Late Relapsed Multiple Myeloma

Laura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma.

Evangelia Vlachou, MD

Evangelia Vlachou, MD, is a postdoctoral research fellow in the Departments of Medical Oncology and Urology at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins.

Latest:

Dr Vlachou on the Rationale for Evaluating Perioperative Enfortumab Vedotin Plus Pembrolizumab in Upper Tract Urothelial CancerCancer

Evangelia Vlachou, MD, discusses the investigation of enfortumab vedotin plus pembrolizumab as perioperative therapy in upper tract urothelial cancer.

Vaishali Sanchorawala, MD

Latest:

First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet Regimens

An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.

Bernard Escudier, MD, Institut Gustave Roussy

Latest:

Evolving Practice Patterns for Advanced Clear Cell Renal Cell Carcinoma

Christine Ryan, MD

Latest:

Dr. Ryan on the Efficacy of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLL

Christine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Siddharth Padia, MD

Latest:

Dr. Padia on the Utility of Y-90 Glass Microspheres in HCC

Siddharth Padia, MD, discusses the utility of TheraSphere™ Yttrium-90 Glass Microspheres in patients with hepatocellular carcinoma.

Yasmin Abaza, MD

Yasmin Abaza, MD, is an assistant professor of medicine (hematology and oncology) at the Feinberg School of Medicine at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Latest:

Dr Abaza on Addressing the Need for Additional Targeted Therapies in AML/MDS

Yasmin Abaza, MD, discusses how the ongoing investigation of emavusertib could address the need for more targeted therapies in AML and MDS.

Catherine E. Lai, MD, MPH

Latest:

Challenges in Treating AML Upon First Remission

Expert perspectives on some of the challenges faced in managing the treatment of patients with AML upon first remission.

Nathaniel Ivanick, MD, FCCP

Latest:

Robotic Navigational Bronchoscopy Advances Diagnosis of Early-Stage Lung Cancer

Nathaniel Ivanick, MD, FCCP, explains advancements in the use of robotic navigational bronchoscopy for the diagnosis of early-stage lung cancer.